Sign In
Buy TRDA
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:45am, Thursday, 15'th Jan 2026
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical st
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 17'th Dec 2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 04'th Dec 2025
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to p
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts
09:30am, Monday, 17'th Nov 2025
Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipe
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
09:30am, Thursday, 06'th Nov 2025
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.35 per share a year ago.
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
07:00am, Thursday, 06'th Nov 2025
-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient coh
Entrada Therapeutics to Present at Upcoming Investor Conferences
07:00am, Tuesday, 28'th Oct 2025
BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Confe
Entrada Therapeutics, Inc. - Special Call
02:57pm, Thursday, 25'th Sep 2025
Entrada Therapeutics, Inc. - Special Call Company Participants Dipal Doshi - CEO & Director Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
07:00am, Friday, 05'th Sep 2025
-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- --
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 02'nd Sep 2025
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units (“RSUs”) and options to
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
09:15am, Wednesday, 06'th Aug 2025
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $1.55 per share a year ago.
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
07:00am, Wednesday, 06'th Aug 2025
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clin
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
11:16am, Thursday, 31'st Jul 2025
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
07:00am, Tuesday, 03'rd Jun 2025
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
